A SOLICITOR who practised for 60 years in Bournemouth, was described as 'a wonderfully eloquent advocate' and likened to ...

X-linked adrenoleukodystrophy (X-ALD) is a debilitating disease caused by mutations in the ABCD1 gene. Approximately 30% of affected boys develop the progressive ...

Viking Therapeutics ( VKTX, Financials) reported its fourth-quarter and full-year 2024 financial results, highlighting ...

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

Subsequent biochemical and genetic analysis revealed that the family was in fact affected by the adrenomyeloneuropathy subtype of X-linked adrenoleukodystrophy. In the family described, both males and ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Given the rise in newborn screening for ALD since 2019, and the untapped potential of existing genetic research, the Halls ...

Viking Therapeutics Inc (VKTX) reports significant R&D progress and financial bolstering despite increased losses and operational challenges.

Stephanie Diaz; Investor Relations Manager; Viking Therapeutics Inc. Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc. Greg Zante; C ...

There may or may not be a connection between my 8-year-old son’s 3 a.m. confession that he knows he might be “going to heaven ...

It’s a rare genetic disorder that impacts a small population, and due to limited research, much remains unknown about treating adrenoleukodystrophy. Now, there’s a new multi-million-dollar fund ...